Compare Inovio Pharmaceuticals Inc (INO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sprott Uranium Miners ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Sprott Uranium Miners ETF trades at $46.36 (market cap $1.87B). The key difference: Sprott Uranium Miners ETF is far larger — about 16.7× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Sprott Uranium Miners ETF for 61 Days on average.
| INO | URNM | |
|---|---|---|
Market Cap | $112.19M | $1.87B |
Volume | 3,201,278 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.65 | $83.99 |
52-Week Low | $0.66 | $46.09 |
Typical Hold Time | 43 Days | 61 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
URNM (Sprott Uranium Miners ETF) trades at $46.43, down 3.01% today amid bearish technical signals. The ETF shows 13 sell signals versus 0 buy signals across moving averages, with oversold RSI readings suggesting potential near-term stabilization. Recent news highlights uranium's strong fundamentals driven by AI power demand and government nuclear investments, though the sector faces volatility from supply-demand imbalances.
Long-term outlook remains positive given nuclear energy's role in AI infrastructure and global decarbonization. Key risks include uranium price volatility and geopolitical supply constraints. Analyst sentiment leans bullish on uranium's structural deficit, with institutional interest growing in pure-play uranium mining exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
